Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. Mosaic's core technology platform is based on Cowpea mosaic virus ("CPMV"), which is non-infectious to humans or other animals but upon intra-tumoral administration, elicits a strong innate immune response resulting in potent antitumor activity against the primary and distant tumor sites. The broad potential of our lead candidate, MIE-101, for the treatment of many different types of cancer and potential combination therapies continues to be supported by numerous publications and grant funding through our university collaborators and co-founders at the UC San Diego Center for Nano-ImmunoEngineering. For additional information about Mosaic, please visit MosaicIE.com.
Company profile
Ticker
CPMV
Exchange
Website
CEO
Carlton Johnson
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PATRIOT SCIENTIFIC CORP
SEC CIK
Corporate docs
Subsidiaries
Mosaic ImmunoEngineering Development Company • Patriot Data Solutions Group, Inc. ...
IRS number
841070278
CPMV stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
15 Apr 24
NT 10-K
Notice of late annual filing
28 Mar 24
8-K
Entry into a Material Definitive Agreement
28 Mar 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Entry into a Material Definitive Agreement
26 Jun 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K
Departure of Directors or Certain Officers
3 May 23
10-K
2022 FY
Annual report
2 Mar 23
RW
Registration withdrawal request
28 Dec 22
Latest ownership filings
4
STEVEN W KING
22 Feb 22
4
GLORIA FELCYN
22 Feb 22
4
ROBERT L GARNICK
22 Feb 22
4
ROBERT BAFFI
22 Feb 22
4
Nicole Franziska Steinmetz
22 Feb 22
3
ROBERT BAFFI
16 Jul 21
4
ROBERT L GARNICK
10 May 21
4
GLORIA FELCYN
10 May 21
4
Nicole Franziska Steinmetz
30 Apr 21
4
Nicole Franziska Steinmetz
29 Jan 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | May 20 | May 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 252.90 k | 252.90 k | 252.90 k | 252.90 k | 252.90 k | 252.90 k |
Cash burn (monthly) | 36.69 k | 10.94 k | 111.08 k | 139.97 k | 36.69 k | 47.02 k |
Cash used (since last report) | 243.95 k | 72.71 k | 738.55 k | 930.61 k | 243.95 k | 312.62 k |
Cash remaining | 8.95 k | 180.18 k | -485.65 k | -677.71 k | 8.95 k | -59.72 k |
Runway (months of cash) | 0.2 | 16.5 | -4.4 | -4.8 | 0.2 | -1.3 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 1.00 k |
Total shares | 4.01 bn |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Western Reserve University Case | 4.01 bn | $0.00 |
West Oak Capital | 1.00 | $1.00 k |